Sign in

IDXG on OTC

INTERPACE BIOSCIENCES, INC.

INTERPACE BIOSCIENCES, INC. is an American surgical and medical instruments and apparatus company.1 It is headquartered in Parsippany, New Jersey.1 Its shares trade on OTC under the symbol IDXG.1

Price unavailable

Last updated Oct 21, 2026.

Overview

Compare with UTAH MEDICAL PRODUCTS INC, RETRACTABLE TECHNOLOGIES INC or Cytosorbents, or pick any stock.

  • TickerIDXG on OTC1
  • IndustrySurgical & Medical Instruments & Apparatus1
  • HeadquartersParsippany, New Jersey1
  • Incorporated inDE2
  • Business addressWaterview Plaza, Suite 310, 2001 Route 46, Parsippany, Nj 070542
  • Filer categoryNon-accelerated filer, Smaller reporting company2
  • Legal formCorporation

See how the biggest companies compare on our leaderboards

Clinical services that help guide patient management decisions by providing information on the diagnosis and prognosis of indeterminate specimens. Guidance on genetic marker-related pharmaceutical treatment options, when available, is also provided.3 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2025

62.3%Gross margin4
10.5%Operating margin4
63.5%Net margin4
-17.5%Revenue growth, 20254
109.9%Return on equity4
$5.5MFree cash flow4

Where the money goes

Where each dollar of revenue went, fiscal 2025

  • Cost of revenue24¢$14.6M
  • Research and development1¢$642.0K
  • Income tax35¢$21.2M
  • Profit40¢$24.6M

Out of $38.7M in revenue.4

Where each dollar of operating cash went, fiscal 2025

  • Capital spending6¢$356.0K
  • Kept or used elsewhere94¢$5.5M

Out of $5.8M of cash from operations.4

Financial statements

Revenue567894$38.7M in 2025+60% since 2019
0$20.0M$40.0M$60.0M2019: $24.2M$24.2M20192020: $32.4M$32.4M2020+34%2021: $33.1M$33.1M2021+2%2022: $31.8M$31.8M2022−4%2023: $40.0M$40.0M2023+26%2024: $46.9M$46.9M2024+17%2025: $38.7M$38.7M2025−17%
Gross profit567894$24.1M in 2025+190% since 2019
0$10.0M$20.0M$30.0M2019: $8.3M$8.3M20192020: $10.7M$10.7M2020+29%2021: $18.8M$18.8M2021+75%2022: $18.2M$18.2M2022−3%2023: $25.1M$25.1M2023+37%2024: $29.9M$29.9M2024+19%2025: $24.1M$24.1M2025−19%
Operating income567894$4.1M in 2025
-$30.0M-$20.0M-$10.0M0$10.0M2019: -$26.4M-$26.4M20192020: -$26.1M-$26.1M2020−1%2021: -$6.3M-$6.3M2021−76%2022: -$3.6M-$3.6M2022−43%2023: $4.0M$4.0M20232024: $8.1M$8.1M2024+105%2025: $4.1M$4.1M2025−50%
Net income567894$24.6M in 2025
-$40.0M-$20.0M0$20.0M$40.0M2019: -$26.7M-$26.7M20192020: -$26.5M-$26.5M2020−1%2021: -$14.9M-$14.9M2021−44%2022: -$22.0M-$22.0M2022+47%2023: $2.0M$2.0M20232024: $6.7M$6.7M2024+243%2025: $24.6M$24.6M2025+267%

Every line of the income statement as filed: the last 2 fiscal years, latest first.4

Period ending2025-12-312024-12-31
Revenue, net$38.7M$46.9M
Cost of revenue$14.6M$17.0M
Gross profit$24.1M$29.9M
Sales and marketing$9.9M$11.7M
Research and development$642.0K$676.0K
General and administrative$9.5M$9.5M
Total operating expenses$20.0M$21.8M
Operating income from continuing operations$4.1M$8.1M
Interest accretion expense-$34.0K
Note payable interest expense-$168.0K-$625.0K
Other expense, net-$142.0K-$499.0K
Income from continuing operations before tax$3.8M$7.0M
(Benefit) provision for income taxes-$21.2M$4.0K
Income from continuing operations$25.0M$6.9M
Loss from discontinued operations, net of tax-$409.0K-$244.0K
Net income$24.6M$6.7M
Less adjustment for preferred stock deemed dividend-$464.0K
Net income attributable to common stockholders$24.6M$6.2M
From continuing operations$6$1
From discontinued operations-$0-$0
Net income (loss) per basic share of common stock$5.55$1.42
From continuing operations$1$0
From discontinued operations-$0-$0
Net income (loss) per diluted share of common stock$0.89$0.40
Basic4.4M shares4.4M shares
Diluted27.7M shares15.7M shares

Compare INTERPACE BIOSCIENCES, INC. with another company

Corporate structure

INTERPACE BIOSCIENCES, INC. sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of INTERPACE BIOSCIENCES, INC.

  • Douglas Mark Singer Filed SCHEDULE 13G/A on INTERPACE BIOSCIENCES, INC., latest Feb 14, 2025 (5 filings since Feb 10, 2022)
  • 1315 Capital II, L.P. Filed SC 13D/A on INTERPACE BIOSCIENCES, INC., latest Oct 16, 2024 (2 filings since Nov 12, 2021)
  • Ampersand 2018 Limited Partnership Filed SC 13D/A on INTERPACE BIOSCIENCES, INC., latest Oct 16, 2024 (2 filings since Nov 12, 2021)
  • Peter H. Kamin Filed SC 13D/A on INTERPACE BIOSCIENCES, INC., latest Feb 1, 2022 (3 filings since Dec 6, 2021)
  • INTERPACE BIOSCIENCES, INC. Parsippany, New Jersey

Built from major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What INTERPACE BIOSCIENCES, INC. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Furniture and fixtures$83.0K4 Dec 31, 2025$83.0K4 Dec 31, 20240%
Computer equipment and software$253.0K4 Dec 31, 2025$253.0K4 Dec 31, 20240%
Leasehold improvements$483.0K4 Dec 31, 2025$483.0K4 Dec 31, 20240%
Property and equipment, before depreciation$4.7M4 Dec 31, 2025$4.2M4 Dec 31, 2024+11.6%
Accumulated depreciation$3.3M4 Dec 31, 2025$2.8M4 Dec 31, 2024+14.9%
Property and equipment, net$1.4M4 Dec 31, 2025$1.4M4 Dec 31, 2024+4.6%
Operating-lease assets (leased space)$1.2M4 Dec 31, 2025$1.6M4 Dec 31, 2024−24.6%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$2.5M4 Dec 31, 2025$1.5M4 Dec 31, 2024+71.5%

Inventory

ItemLatestA year beforeChange
Inventory, total$1.1M4 Dec 31, 2025$1.2M4 Dec 31, 2024−8.0%

Properties, in its own words

Our corporate headquarters are located in Parsippany, New Jersey. Our Parsippany, New Jersey lease is month-to-month. Our diagnostic laboratory facility is located in Pittsburgh, Pennsylvania where we lease approximately 21,400 square feet. Our Pittsburgh, Pennsylvania lease runs through June 30, 2028.

We believe that our current facilities are adequate for our current and foreseeable operations and that suitable additional space will be available if needed.

Item 2 of the 10-K filed Mar 30, 2026.3

Leadership

Who has led INTERPACE BIOSCIENCES, INC., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Michael Marquard2006–2008
  2. Nancy Lurker2008–2015
  3. Robert Owen Likoff2010
  4. Jack E. Stover2016–2020
  5. Thomas W. Burnell2020–now

Chair

  1. Thomas W. Burnell2026–now

President

  1. Stephen Cotugno2006
  2. Steven K. Budd2006
  3. Kevin Connolly2006
  4. Howard Drazner2009–2010
  5. Peter Tilles2009
  6. Gerald R. Melillo Jr.2013–2015
  7. Jack E. Stover2016–2020
  8. Thomas W. Burnell2020–now

Chief financial officer

  1. James G. Farrell2008
  2. Graham G. Miao2014–2015
  3. Nat Krishnamurti2016
  4. James Early2016–2020
  5. Fred S. Knechtel2020
  6. Thomas John Freeburg2021
2010201520202025
Board members and other officers (32)

Named in SEC Form D filings

People the company listed in its private-offering notices.

  • Chief Financial OfficerChristopher W. McCarthy named Oct 16, 202462

Former names

  • Interpace Diagnostics Group, Inc.Dec 23, 2015 to Nov 1, 20192
  • PDI INCNov 14, 2002 to Dec 22, 20152
  • PROFESSIONAL DETAILING INCMay 13, 1998 to Nov 13, 20022

Timeline

  1. Oct 15, 20268-K Results of operations63
  2. Aug 27, 20268-K Bylaws or fiscal year changed; Regulation FD disclosure64
  3. Aug 26, 20268-K Executive or director change65
  4. Aug 21, 20268-K Shareholder vote66
  5. Aug 12, 20268-K Results of operations67
  6. May 14, 20268-K Results of operations68
  7. Apr 1, 20268-K Results of operations69
  8. Jan 20, 20268-K Results of operations; Regulation FD disclosure70
  9. Dec 3, 20258-K Other events71
  10. Nov 12, 20258-K Results of operations72
  11. Aug 8, 20258-K Results of operations73
  12. May 8, 20258-K Results of operations74
  13. Dec 2, 2020New chief executive Thomas W. Burnell becomes CEO13
  14. Feb 5, 2016New chief executive Jack E. Stover becomes CEO14
  15. Nov 16, 2010New chief executive Robert Owen Likoff becomes CEO15
  16. Nov 24, 2008New chief executive Nancy Lurker becomes CEO16
  17. May 22, 2006New chief executive Michael Marquard becomes CEO17

Calendar

When it reported results

  1. Oct 15, 2026Reported quarterly or annual results63
  2. Aug 12, 2026Reported quarterly or annual results67
  3. May 14, 2026Reported quarterly or annual results68
  4. Apr 1, 2026Reported quarterly or annual results69
  5. Jan 20, 2026Reported quarterly or annual results70
  6. Nov 12, 2025Reported quarterly or annual results72
  7. Aug 8, 2025Reported quarterly or annual results73
  8. May 8, 2025Reported quarterly or annual results74

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

128 filings to the SEC since October 2021: 10 annual reports, 15 quarterly reports, 49 major events, 16 insider forms, 12 large holders, 1 private raises, 25 other. The latest 20:

  1. Oct 15, 2026FWP EDGAR
  2. Oct 15, 20268-K EDGAR
  3. Oct 1, 2026S-1/A EDGAR
  4. Sep 25, 2026S-1 EDGAR
  5. Sep 17, 2026S-8 EDGAR
  6. Aug 27, 20268-K EDGAR
  7. Aug 26, 20268-K/A EDGAR
  8. Aug 21, 20268-K EDGAR
  9. Aug 20, 20264 EDGAR
  10. Aug 20, 20264 EDGAR
  11. Aug 20, 20264 EDGAR
  12. Aug 20, 20264 EDGAR
  13. Aug 20, 20264 EDGAR
  14. Aug 20, 20264 EDGAR
  15. Aug 12, 20268-K EDGAR
  16. Aug 10, 202610-Q EDGAR
  17. Jul 22, 2026DRS EDGAR
  18. Jul 7, 2026DEFA14A EDGAR
  19. Jul 7, 2026DEF 14A EDGAR
  20. Jun 25, 2026PREM14A EDGAR

The 128 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Executive pay

What the company paid its top executives, from the summary compensation table in its proxy statement. Total pay includes salary, bonus, stock and option awards and other pay, as the company valued them.

YearExecutiveAgeSalaryTotal pay
2025CEOPresident and Chairman of the Board$460.6K$708.2K79
2025CFO and COO$325.0K$468.3K79
2024CEOPresident and Chairman of the Board$456.5K$703.8K79
2024CFO and COO$274.6K$434.5K79

Money raised

Private offerings the company reported to the SEC on Form D.

  1. Oct 11, 2024Raised $47 million in a private offering of equity Form D: 2 investors so far Form D

SEC filer profile

How INTERPACE BIOSCIENCES, INC. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARINTERPACE BIOSCIENCES, INC.1
  • CIK0001054102
  • Employer ID (EIN)22-29194863
  • Filer statusNon-accelerated filer not an emerging growth company; a smaller reporting company; a shell company3
  • Incorporated inDelaware3
  • Fiscal year endsDecember 311
  • Industry code (SIC)3841 Surgical & Medical Instruments & Apparatus1
  • SEC reviewing officeOffice of Industrial Applications and Services, Division of Corporation Finance1
  • Business addressWaterview Plaza, Suite 310, 2001 Route 46, Parsippany, NJ 070541
  • Phone412-224-61001
  • Shares outstanding27,700,904 as of Jul 31, 202611
  • Public float$2.6M as of Jun 30, 20253
  • AuditorEISNERAMPER LLP, Philadelphia, Pennsylvania PCAOB ID 274; no auditor attestation of internal control over financial reporting3
  • On EDGAR sinceFeb 13, 19981
  • Filings1,134 in all: 8-K (317), 4 (266), 10-Q (85), 3 (57), SC 13G/A (56), CORRESP (30), DEF 14A (28), 10-K (27)1
    All 50 form types

    SC 13G (24), 8-K/A (21), UPLOAD (20), SC 13D/A (19), 10-K/A (17), 4/A (17), DEFA14A (17), 5 (15), PRE 14A (10), S-1/A (10), S-8 (10), 10-Q/A (9), 424B5 (9), D (5), EFFECT (5), S-3 (5), S-3/A (5), SC 13D (5), CT ORDER (4), S-1 (4), SC TO-I/A (4), 424B3 (3), NT 10-Q (3), S-8 POS (3), 10-K405 (2), 424B4 (2), DEFR14A (2), NT 10-K (2), PREM14A (2), SCHEDULE 13G/A (2), 25-NSE (1), 424B1 (1), 424B2 (1), 8-A12G (1), DEFM14A (1), DRS (1), FWP (1), POS AM (1), POS EX (1), RW (1), S-1MEF (1), SC TO-I (1)

  • Latest filingsAnnual report (10-K) Mar 30, 2026
    Quarterly report (10-Q) Aug 10, 2026
    Proxy statement (DEF 14A) Jul 7, 2026
    Latest 8-K (8-K) Oct 15, 2026

Risk factors and legal proceedings

The risks INTERPACE BIOSCIENCES, INC. names in Item 1A of its 10-K filed Mar 30, 2026: 63 risks under these headings, as written.3

  • Risks Related to our Business
  • We depend on a few payers for a significant portion of our revenue for our clinical services, and if one or more significant payers, including CMS, stops providing reimbursement as CMS did with our now discontinued PancraGEN® test, or decreases the amount of reimbursement for our tests, or if we are unable to successfully negotiate additional reimbursement contracts for our clinical services tests, our revenue could decline and our commercial success could be compromised.
  • Our quarterly and annual revenues and operating results may vary, which may cause the price of our common stock to fluctuate.
  • We depend on sales and reimbursements from our clinical services for all of our revenue, and we will need to generate sufficient revenue from these and other products and/or solutions that we develop or acquire to grow our business.
  • We rely on third parties to process and transmit claims to payers for our clinical services, and any delay in processing or transmitting could have an adverse effect on our revenue and financial condition.
  • Due to how we recognize revenue, our quarterly revenue and operating results are likely to fluctuate.
  • A deterioration in the collectability of our accounts receivable could have a material adverse effect on our business, financial condition and results of operations.
  • Our business is substantially dependent on third-party reimbursement. Any change in the overall health care reimbursement system may adversely impact our business.
  • Our inability to finance our business on acceptable terms in the future may limit our ability to develop and commercialize products and services and grow our business.
  • Risks Related to our Preferred Stock
  • We may issue additional preferred stock in the future, and the terms of the preferred stock may reduce the value of our common stock.
  • Two private equity firms and their affiliates control an aggregate of 84% of our outstanding shares of common stock and this concentration of ownership may have a substantial influence on our decisions.
The other 53 risks
  • Risks Related to our Clinical Services
  • Billing for our clinical services tests is complex, and we must dedicate substantial time and resources to the billing process to be paid for our clinical services tests.
  • If payers do not provide reimbursement, rescind or modify their reimbursement policies or delay payments for clinical services, or if we are unable to successfully negotiate additional reimbursement contracts for our clinical services tests, our commercial success could be compromised.
  • We may experience a reduction in revenue if physicians decide not to order our clinical services tests.
  • We may experience a reduction in revenue if patients decide not to use our clinical services tests.
  • If our clinical services tests do not perform as expected, we may not be able to achieve widespread market adoption among physicians, which would cause our operating results, reputation, and business to suffer.
  • Clinical utility studies are important in demonstrating to both customers and payers a molecular diagnostic test’s clinical relevance and value. If we are unable to identify collaborators willing to work with us to conduct clinical utility studies, or the results of those studies do not demonstrate that a molecular diagnostic test provides clinically meaningful information and value, commercial adoption of such test may be slow, which would negatively impact our business.
  • Our existing clinical utility studies may be outdated and may not reflect current medical practice, which could adversely affect acceptance of our products and services.
  • We rely on sole suppliers for some of the materials used in our tests and services, and we may not be able to find replacements or transition to alternative suppliers in a timely manner.
  • We may experience problems in scaling our operations, or delays or reagent and supply shortages for our tests and services that could limit the growth of our revenue.
  • If we are unable to support demand for our tests and services, or any of our future tests, services or solutions, our business could suffer.
  • Developing new tests and related services and solutions involves a lengthy and complex process, and we may not be able to commercialize on a timely basis, or at all, other tests, assays, services and solutions under development.
  • If we are unable to develop or acquire tests, services and solutions to keep pace with rapid technological, medical and scientific change, our operating results and competitive position in the market could be affected.
  • If we cannot enter into new clinical study collaborations, our product development and subsequent commercialization could be delayed.
  • FDA implementation of the LDT final rule would have a material adverse effect on our clinical services and/or cause us to incur substantial costs and delays associated with trying to obtain pre-market clearance or approval and comply with applicable pre- and post-market requirements.
  • Evolving regulation of algorithm-based and bioinformatics tools could increase compliance obligations.
  • If we are sued for product liability or errors and omissions liability related to our tests and services, we could face substantial liabilities that exceed our resources.
  • Our failure to comply with fraud and abuse laws or payer regulations could result in our being excluded from participation in Medicare, Medicaid, or other governmental payer programs, subject to fines, penalties, and repayment obligations, decrease our revenues and adversely affect our results of operations and financial condition for our clinical services.
  • Risks Related to our Operations
  • We may not be able to successfully implement future restructuring activities or other significant organizational changes.
  • The loss of members of our senior management team or our inability to attract and retain key personnel could adversely affect our business.
  • If we lose the support of key opinion leaders, it may limit our revenue growth from our tests or services and our ability to achieve profitability.
  • If our sales force is less successful than anticipated, our business expansion plans could suffer and our ability to generate revenues could be diminished.
  • If we are unable to compete successfully in the markets our clinical services operate in, we may be unable to increase or sustain our revenue or achieve profitability.
  • If we cannot license rights to use third-party technologies on reasonable terms, we may not be able to commercialize new products or services in the future.
  • Unfavorable results of legal proceedings could have a material adverse effect on our business, financial condition and results of operations.
  • If a catastrophe strikes our laboratory or if it becomes inoperable for any other reason, we will be unable to perform our testing and our business will be harmed.
  • If we use hazardous materials in a manner that causes contamination or injury, we could be liable for resulting damages.
  • Security breaches, loss of data and other disruptions to us or our third-party service providers could compromise sensitive information related to our business or prevent us from accessing critical information and expose us to liability, which could adversely affect our business and our reputation.
  • We may need to increase the size of our organization, and we may experience difficulties in managing this growth.
  • Risks Related to Regulation within our Markets
  • If we fail to comply with federal, state and foreign laboratory licensing requirements, we could lose the ability to perform our tests or experience disruptions to our business.
  • Legislation reforming the U.S. healthcare system may have a material adverse effect on our financial condition and operations.
  • Complying with numerous statutes and regulations pertaining to our services is an expensive and time-consuming process, and any failure to comply could result in substantial penalties.
  • A failure to comply with federal and state laws and regulations pertaining to our payment practices could result in substantial penalties.
  • Our business activities may be subject to the Foreign Corrupt Practices Act, or FCPA, and similar anti-bribery and anti-corruption laws.
  • Changes in governmental regulation could negatively impact our business operations and increase our costs.
  • Risks Relating To Our Intellectual Property
  • If we are unable to protect our intellectual property effectively, our business would be harmed.
  • Changes in U.S. patent law could diminish the value of patents in general, thereby impairing our ability to protect our molecular diagnostic tests.
  • We may be involved in litigation related to intellectual property, which could be time-intensive and costly and may adversely affect our business, operating results or financial condition.
  • Other Risks Related to our Business
  • Our ability to use our net operating loss carryforwards may be limited and may result in increased future tax liability to us.
  • Comprehensive tax reform could adversely affect our business and financial condition.
  • Global economic and political instability and geopolitical events could adversely affect our business, financial condition or results of operations.
  • We may acquire businesses or assets or make investments in other companies or testing, service or solution technologies that could harm our operating results, dilute our stockholders’ ownership, increase our debt or cause us to incur significant expense.
  • If our information technology or communications systems fail or we experience a significant interruption in their operation, our reputation, business and results of operations could be materially and adversely affected.
  • Risks Related To Our Common Stock Price
  • The price and trading volume of our common stock may be highly volatile and could be further affected by events not within our control, and an investment in our common stock could suffer a decline in value.
  • The issuance of additional shares of our common stock in any future offerings could be dilutive to stockholders.
  • The delisting of our common stock from Nasdaq has adversely affected our common stock and business and financial condition.
  • The risks associated with penny stock classification could affect the marketability of the Company’s common stock and stockholders could find it difficult to sell their shares.
  • Risks Relating to Being a Public Company
  • We will continue to incur increased costs and demands on management as a result of compliance with laws and regulations applicable to public companies, which could harm our operating results.
  • If we are unable to maintain and implement effective internal controls over financial reporting, investors may lose confidence in the accuracy and completeness of our reported financial information and the market price of our common stock may be negatively affected.
  • Risks Relating to Our Corporate Structure and Our Common Stock
  • We have a substantial number of authorized shares of common and preferred stock available for future issuance that could cause dilution of our stockholders’ interest, adversely impact the rights of holders of our common stock and cause our stock price to decline.
  • Any weakness in our disclosure controls and procedures and our internal controls could have a material adverse effect on us.
  • We have anti-takeover defenses that could delay or prevent an acquisition and could adversely affect the price of our common stock.
  • We may be subject to securities litigation, which is expensive and could divert our management’s attention.
  • The indemnification rights provided to our directors, officers and employees may result in substantial expenditures by us and may discourage lawsuits against its directors, officers, and employees.

Legal proceedings

We are not currently a party to any material legal proceedings. We may from time to time become involved in legal proceedings arising in the ordinary course of business.

The opening of Item 3, Legal Proceedings.3

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
  48. 48
  49. 49
  50. 50
  51. 51
  52. 52
  53. 53
  54. 54
  55. 55
  56. 56
  57. 57
  58. 58
  59. 59
  60. 60
  61. 61
  62. 62
  63. 63
  64. 64
  65. 65
  66. 66
  67. 67
  68. 68
  69. 69
  70. 70
  71. 71
    SEC EDGAROther events
  72. 72
  73. 73
  74. 74
  75. 75
  76. 76
  77. 77
  78. 78
  79. 79